← Oncology Approval Tracker

FDA DECISION ·

Kymriah

tisagenlecleucel · Novartis

Accelerated approvalNew or expanded indicationFollicular lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory follicular lymphoma after at least two lines of systemic treatment.

LAMPGEN ANALYSIS

Why it matters

This extends the CD19-directed CAR T-cell product to a later-line indolent lymphoma population.

What research teams should watch

Confirm the follicular lymphoma diagnosis and prior lines before starting a cellular-therapy referral.

PRIMARY RECORDS

Sources